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ABSTRACT 
 
Tumor incidence for renal cell carcinoma is two-fold higher in males than in females. 
Members of the protein kinase C (PKC) gene family have been shown to be relevant for 
carcinogenesis. However, little is known about a possible gender specific role of PKC in renal 
cell carcinoma (RCC). In this study, we quantified expression of eleven PKC-isoforms in 
clear cell RCCs (ccRCC) and in the corresponding normal renal tissue. A possible association 
of PKC-isoforms with gender of the patients was examined. Tissue specimens of 27 patients, 
14 males and 13 females, with ccRCC and of the corresponding normal renal tissue were 
examined. Expression of PKC-isoforms were detected by Western blot analysis and 
quantified by computer-aided integration. In ccRCCs, as well as in the corresponding normal 
renal tissue, all PKC-isoforms except PKCγ and θ were detectable. Clear associations with 
gender of the patients were observed: (i) PKCδ was reduced in tumor tissue of female patients 
(p = 0.023), but not of male patients (p = 0.198). (ii) A 3.6-fold enhanced expression of the 
oncogene PKCη was found in tumor tissue of female compared to male patients (p = 0.049). 
Gender specific differences in PKCδ as well as PKCη expression suggest that different 
molecular mechanisms are relevant for carcinogenesis of ccRCC in male and female patients. 
This may become important for classification and treatment of ccRCC. 
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INTRODUCTION 
 
The incidence of renal cancer is 
approximately two-fold higher in males than 
in females (deKernion et al., 1992). 
Furthermore, a gender specific difference in 
the prognosis of renal clear cell carcinoma 
has been shown: women had a more 
favorable prognosis with longer survival than 
men (Onishi et al., 2002; McNichols et al., 
1981; Lieber et al., 1981). However, the 
influence of gender on prognosis is discussed 
controversially (Nurmi, 1984). 
Signal transduction pathways that regulate 
cell proliferation, apoptosis and migration 
are critical for development of renal cell 
cancer (Brenner et al., 1995). Usually, tumor 
development is caused by an upregulation of 
oncogenes and/or a downregulation of tumor 
suppressors. 
The most important signal transduciton 
pathways that regulate cell proliferation and 
apoptosis are the ras/MAP-kinase pathway 
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and the Akt/PKB pathway. Involved in these 
two pathways are the protein kinases C 
(PKC). PKC is a family of eleven 
serine/threonine kinases which play a critical 
role in the regulation of multiple cellular 
mechanisms such as cell differentiation, cell 
growth, migration, apoptosis and tumor 
development (Mellor et al., 1998; Brenner et 
al., 2000). 
Because the PKC isoforms display 
substantial differences in enzymatic 
activities, tissue and intracellular distribution 
and cofactor requirements, they might have 
different physiological roles (Oehrlein et al., 
1998; Goodnight et al., 1994). A point of 
interest is the identification of specific 
physiological meanings of each isoform for 
tumor cells. PKCε overexpression results in 
general in tumorigenesis, leading to its 
classification as an oncogene (Cacace et al., 
1993). Oncogenic properties are also known 
for the isoforms PKCη and PKCζ 
(Schonwasser et al., 1998; de Thonel et al., 
2001; Nishizuka et al., 1995). In contrast, 
PKCα and PKCδ appear to play a role as 
tumor suppressors (Brooks et al., 1993; Lu et 
al., 1997; Fukomoto et al., 1997). Since 
ccRCC development is a multifactoral 
phenomen and twice as often in men than in 
women, we investigated the role of the 
various PKC-isoforms and their expression 
pattern in male and female patients with 
ccRCC. 
In the present study, we determined the 
expression of eleven PKC-isoforms in 
ccRCC tissue as well as in the corresponding 
normal renal tissue of 14 males and 13 
females. For this purpose we extracted 
protein from 27 ccRCCs and quantified the 
PKC-isoforms by Western blot analysis. The 
resulting PKC values were correlated with 
the gender and age of the patients. 
 
MATERIALS AND METHODS 
 
Patients and tissue specimens 
Tissue specimens were obtained under 
sterile conditions from 27 patients, 14 males 
and 13 females, with primary ccRCC. All 
patients had undergone nephrectomies at the 
Department of Urology of the Johannes 
Gutenberg-University, Mainz, Germany. 
From these patients, tissue specimens from 
normal and malignant renal tissue (5x5x5 
mm) were shock frozen in liquid nitrogen 
and stored at -80°C until needed (Reutzel et 
al., 2001). Normal and tumor tissue were 
taken from the same kidney, whereby the 
normal tissue was located at least 3 cm from 
the edge of the tumor. Because the precursor 
cells of ccRCCs are proximal tubulus 
epithelial cells, which are initially located in 
the cortex of the kidney, non malignant tissue 
specimens were obtained from the cortex for 
our experiments. The diagnosis of ccRCC 
and the histological classification of all 
tumor tissue specimens used in this study 
was confirmed by a pathologist. Grading and 
staging were done according to the 
International Union Against Cancer 
(Wittekind et al., 1997; Brauch et al., 2000). 
Because of limited amount of tissue, in five 
cases investigations could be determined 
only for part of the PKC isoforms. 
 
Preparation of protein extract 
For preparation of protein extracts, the 
renal tumor tissue and normal renal tissue 
specimens were crushed with a mortar under 
liquid nitrogen (Schiffer et al., 2003) and 
suspended in lysis buffer at 4°C (20 mM 
Hepes, pH 7.7, 0.2 M NaCl, 1.5 mM MgCl2, 
0.4 mM EDTA, 1% Triton X-100, 0.5 mM 
DTT, 100 µg/ml leupeptin, 100 µg/ml 
aprotinin, 10 mM benzamidine, 2 mM 
phenylmethylsulphonyl fluoride, 20 mM β-
glycerophosphate and 0.1 mM sodium-ortho-
vanadate; Brenner et al., 2002). Protein 
concentrations of the supernatants were 
determined using Bicinchoninic acid reagents 
(Hengstler et al., 1999b; von Mach et al., 
2003). 
 
Western blot analysis 
The primary antibodies against the PKC-
isoforms used for Western blotting as well as 
dilution factors and the apparent molecular 
mass of the antigen are listed in table 1. The 
horseradish peroxidase-conjugated goat-anti-
rabbit or rabbit-anti-mouse antibodies were 
obtained from DAKO (Hamburg, Germany), 
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the horseradish peroxidase-conjugated 
donkey-anti-goat was obtained from Santa 
Cruz Biotechnology (Santa Cruz, California, 
USA). 
Protein was separated by SDS-PAGE 
(sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis; Brenner et al., 1995) in 10% 
acrylamide gels and transferred by semi-dry 
blotting onto polyvinylidene fluoride 
membranes (PVDF, Immobilon P, Millipore, 
Bedford, MA) for Western blotting. For 
Western blot analysis of PKC isoforms, a 
protein extract of the embryonic carcinoma 
stem cell line PCC7-Mz1, which expresses 
all PKC isoforms (Oehrlein et al., 1998), was 
always run in parallel as positive control. The 
membrane was blocked in 0.1% Triton X-
100, 5% low fat milk powder in PBS for one 
hour (Fritz et al., 1997). The primary 
antibodies were incubated overnight at 4°C, 
diluted according to table 1 in 0.1% Triton, 
1% low fat milk powder and 0.1% BSA 
(bovine serum albumine) in PBS. After 
washing three times with 0.1% Triton X-100 
in PBS, the membrane was incubated with 
horseradish peroxidase-conjugated secondary 
antibodies for one hour at room temperature. 
The bound antibodies were visualized by 
enhanced chemiluminescence (ECL) 
detection system using Fuji medical X-ray 
films. To check the specificity of the signals 
detected by Western blot, the primary 
antibodies were preadsorbed with the 
corresponding blocking peptide for 10 min. 
Afterwards, Western blot analyses were 
performed as described above. Signals were 
considered as specific when the bands 
reflecting PKC did not show up after this 
pretreatment. After exposure to X-ray film, 
the Western blot membrane was stained with 
Coomassie brilliant blue (Sigma, 
Deisenhofen, Germany) and the amount of 
total protein was calculated by integration of 
the bands of each lane using Sigma gel 1.0 
software (Brenner et al., 1999; Hengstler et 
al., 1998). 
 
 
Table 1: Antibodies for Western blot analysis of the eleven PKC-isoforms (p = polyclonal, m = 
monoclonal), Antibodies marked with P.P. were kindly provided by Peter Parker, London, Great 
Britain. 
 
PKC 
Antibodies 
Supplier Type Species Dilution 
Factors 
Apparent molecular 
mass of Antigen (kDA) 
anti-PKCα UBI m Mouse 1:2000 82 
anti-PKCβI P.P p Rabbit 1:2000 96 
anti-PKCβII Santa Cruz p Rabbit 1:2000 80 
anti-PKCγ Sigma m Mouse 1:2000 80 
anti-PKCδ Santa Cruz p Rabbit 1:2000 80 
anti-PKCε Santa Cruz p Rabbit 1:2000 93 
anti-PKCη Santa Cruz p Rabbit 1:2000 80 
anti-PKCθ Santa Cruz p Rabbit 1:2000 79 
anti-PKCζ P.P. p Rabbit 1:2000 75 
anti-PKCι / λ Transduction 
Laboratories 
m Mouse 1:2000 74 
anti-PKCµ Santa Cruz p Rabbit 1:2000 116 
 
 
Evaluation of PKC content 
The amount of separated whole protein 
was calculated after staining of the Western 
blot membrane with Coomassie brilliant blue 
and integration of all spots by Sigma gel 1.0 
software. The intensities of the signals of 
PKC-isoforms on the X-ray film were 
referred to the whole amount of analyzed 
protein on the respective sample. The in this 
way calculated values were defined as 
“densitometric units”. To assess a potentially 
development of expression during carcino-
genesis of ccRCC, the relative expression of 
PKC was calculated. Therefore, the 
densitometric units of tumor tissue were 
divided through the densitometric units of the 
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corresponding normal renal tissue of the 
same patient. 
 
Statistical analysis 
The ratio between PKC expression in 
tumor tissue and in the corresponding normal 
tissue was calculated. Possible association of 
these ratios with gender and age were 
evaluated using the two-sided Mann-Whitney 
test (Hengstler et al., 1999a). Statistical 
analysis was performed using SPSS 10.0 
software (SPSS Inc., Chicago, USA). 
 
RESULTS 
 
Association of PKC expression with sex and 
age 
Expression of all eleven PKC-isoforms 
was determined in ccRCC tissue specimens 
and in the corresponding normal renal 
tissues. We observed that two of the PKC-
isoforms, namely PKCδ and η, were 
influenced by patient’s gender. In females, a 
decrease in PKCδ expression was observed 
in ccRCC versus normal renal tissue (median 
82.9%; Q1 62.6%; Q3 100.8; p = 0.023). No 
major difference in PKCδ was measured for 
male patients between ccRCC and normal 
tissue (median 109.2%; Q1 90.7%; Q3 
141.7%; p = 0.198). The difference in ratios 
of PKCδ expression (ccRCC divided by 
normal tissue) between male and female 
patients was significant with p = 0.019 (Fig. 
1). 
A further difference between male and 
female patients was observed for PKCη. The 
ratios (ccRCC divided by normal tissue) 
were higher in female (median 361.9%; Q1 
99.4%; Q3 1000.0%; p = 0.035) as compared 
to male patients (median 93,2%; Q1 29,8%; 
Q3 185,0%; Fig. 2). A difference between 
ccRCC and normal tissue could be detected 
only for females (p = 0.049). A correlation 
between the PKC expression and the age of 
the patients was not detectable. 
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Figure 1: Expression of PKCδ in relation to 
gender. PKCδ expression in tumor tissue in 
percent of the corresponding normal renal tissue. 
In females, PKCδ was reduced by about 24% (p 
= 0.019) compared to the nearly unaltered 
expression in males. Box plots show medians 
(central lane), 25% and 75% percentiles (lower 
and upper side of the box) and minimum and 
maximum (lower and upper bars). 
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Figure 2: Expression of PKCη in relation to 
gender. PKCη expression in tumor tissue in 
percent of the corresponding normal renal tissue. 
Expression of PKCη was 3.9-fold higher in 
females compared to males (p = 0.035). In 
addition, PKCη was 3.6-fold enhanced compared 
to normal renal tissue in females. Box plots show 
medians (central lane), 25% and 75% percentiles 
(lower and upper side of the box) and minimum 
and maximum (lower and upper bars). 
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DISCUSSION 
 
We studied the expression of eleven PKC-
isoforms in ccRCC tissue specimens and the 
corresponding normal renal tissues of 27 
patients. PKC is involved in regulation of 
cell growth, differentiation and apoptosis. 
However, the role of the different PKC 
isoforms in gender specific carcinogenesis is 
not investigated until now. We examined 
whether PKC expression differed between 
normal and tumor tissue and if it was 
associated with gender. 
Expression of PKCδ in females was 
significantly lower in ccRCC tissue com-
pared to the respective normal renal tissue (p 
= 0.023). In male patients, no difference of 
PKCδ expression in ccRCC tissue compared 
to normal tissue was observed. PKCδ is a 
well known tumor suppressor with several 
established anti-carcinogenic mechanisms: 
(i) inhibition of cell cycle progression by 
antagonisation of the Jak-STAT signaling 
pathway (Saharinen et al., 1997); (ii) 
inhibition of phospholipase D (antagonizing 
Raf activation; Goekjian and Jirousek 1999) 
and (iii) phosphorylation of lamin B leading 
to apoptosis (Cross et al., 2000). 
Interestingly, expression of PKCδ has been 
reported to be estrogen dependent in some 
cell types (Shanmugam et al., 1999), a 
possible explanation for gender specific 
expression. Furthermore, induction of PKCδ 
in transgenic mice resulted in a more 
pronounced reduction of papilloma in males 
than in females (Reddig et al., 2000), which 
lead to the speculation that tumors of males 
are more sensitive against alteration of PKCδ 
expression than of females. Perhaps, female 
tumors require a stronger reduction of the 
tumor suppressor PKCδ to trigger 
carcinogenesis, whereas in male patients 
tumor development may occur even with 
unaltered PKCδ levels. This theory would 
explain the reduced expression of PKCδ in 
female renal cell carcinomas (Fig. 2). 
Expression of PKCη did not differ 
between ccRCC and normal renal tissue in 
males. However, a more than three-fold 
increase in mean PKCη expression was 
observed in females in ccRCC compared to 
normal renal tissue (p = 0.049). PKCη has 
been described to be associated with 
histological grading: tumors with grading 3 
and 4 expressed about three-fold more PKCη 
than grade 1 and 2 tumors (Brenner et al., 
2003). PKCη has been discussed to function 
as an oncogene because it is involved in 
activation of Raf (Schonwasser et al., 1998). 
This might explain the role of PKCη in 
progression of ccRCC, although an 
association with increased Raf signaling and 
proliferation has not yet been examined in 
ccRCC. In contrast to PKCη, expression of 
other oncogenes like c-met or bcl-2 did not 
correlate with gender (Nakopoulou et al., 
1997; Takayama et al., 1996). 
The described gender specific expression 
of PKC isoenzymes seems to be dependent 
on cell type and species. In rat liver, Zangar 
et al. found a gender specific expression of 
the oncogenic PKCα isoform with an 
enhanced expression in females (Zangar et 
al., 1995). 
The more distinct downregulation of the 
tumor suppressor PKCδ and high level of 
oncogene PKCη in females does not imply a 
worse outcome. In contrast, female patients 
with ccRCC have a better survival rate than 
male patients (Onishi et al., 2002; 
McNichols, 1981), although other studies 
describe no differences in prognostic 
outcome of males versus females (Kirkali et 
al., 2001, Congregado et al., 2001). 
However, males seem to be more sensitive 
against treatment with Interleukin 2 
compared to females (Elias and Hunt, 2001). 
Obviously, different molecular mechanisms 
contribute to renal carcinogenesis in male 
and females. For renal carcinogenesis in 
females, a stronger reduction of tumor 
suppressors and increase of oncogenes is 
perhaps required. This may be one reason for 
the two-fold higher incidence of RCC in 
males than in females. Furthermore, PKCδ 
seems to represent a tumor suppressor that is 
relevant for pathogenesis of ccRCC in 
females. 
The main findings of this study, a more 
pronounced reduction of the tumor 
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suppressor PKCδ in tumors of female 
compared to male patients and an increased 
expression of the oncogene PKCη in tumors 
of female but not male patients suggest 
gender specific molecular mechanisms of 
carcinogenesis in ccRCC. In females, 
carcinogenesis of ccRCC seems to be 
associated with a stronger reduction of the 
tumor supressor PKCδ and a stronger 
enhancement of the oncogene PKCη. This 
may play a role for classification of ccRCC 
and for females treating with PKCη specific 
inhibitors. 
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